The plenary sessions on regenerative medicine at BIO Asia-Taiwan 2026 convened world-renowned researchers to evaluate the translation of laboratory cell engineering into scalable clinical therapies. As cell-based therapeutics transition into advanced human trials, the global biotechnology sector faces complex engineering, regulatory, and health-economic hurdles. While early trials established proof-of-concept for tissue repair, developing standardized, reproducible … Living Drugs, Scaled Future: Unlocking the Next Era of Cell Therapies Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.